TAZOCIN POWDER FOR SOLUTION

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

PIPERACILLIN (PIPERACILLIN SODIUM); TAZOBACTAM (TAZOBACTAM SODIUM)

可用日期:

PFIZER CANADA ULC

ATC代码:

J01CR05

INN（国际名称）:

PIPERACILLIN AND BETA-LACTAMASE INHIBITOR

剂量:

3G; 375MG

药物剂型:

POWDER FOR SOLUTION

组成:

PIPERACILLIN (PIPERACILLIN SODIUM) 3G; TAZOBACTAM (TAZOBACTAM SODIUM) 375MG

给药途径:

INTRAVENOUS

每包单位数:

17.36ML

处方类型:

Prescription

治疗领域:

EXTENDED-SPECTRUM PENICILLINS

產品總結:

Active ingredient group (AIG) number: 0225919003; AHFS:

授权状态:

CANCELLED POST MARKET

授权日期:

2015-02-26

产品特点

_ _
_TAZOCIN (Piperacillin Sodium/Tazobactam Sodium)_
_ _
_Page 1 of 43 _
PRODUCT MONOGRAPH
PR
TAZOCIN
®
Piperacillin and Tazobactam powder for injection
2.0g/0.25g, 3g/0.375g, 4.0g/0.5g per vial (as piperacillin sodium and
tazobactam sodium)
Lyophilized Powder for Injection
Antibiotic/ß-lactamase Inhibitor
Pfizer Canada Inc
17,300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
Date of Revision:
April 8, 2014
Submission Control No: 171562
®
TM Wyeth Holdings Corporation, Pfizer Canada Inc., Licensee
_ _
_TAZOCIN (Piperacillin Sodium/Tazobactam Sodium)_
_ _
_Page 2 of 43 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................5
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................14
OVERDOSAGE
................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
............................................................20
STORAGE AND STABILITY
..........................................................................................23
SPECIAL HANDLING INSTRUCTIONS
.......................................................................23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................23
PART II: SCIENTIFIC INFORMATION
....